Pink Sheet is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction

J&J Not Sweating Remicade Biosimilar Approval

This article was originally published in The Pink Sheet Daily

Executive Summary

The company remains comfortable with the growth outlook for pharmaceuticals despite FDA approval of a rival biosimilar to its blockbuster Remicade, the firm said during its first quarter conference call.

You may also be interested in...



2Q Pharma Results Preview: What Lies Ahead

The big pharma financial reporting season gets underway on July 19 with Novartis and Johnson & Johnson in the vanguard. Biosimilar threats to immunology and cancer drugs and new product ramp-ups are among the key things to watch for as results are announced.

Rocket Fires Up CV Gene Therapy Pipeline With Renovacor Merger

Rocket's all-stock acquisition of Renovacor is valued at about $53m and adds a preclinical portfolio targeting genetically driven cardiovascular disease.

Virios Fibromyalgia Drug Fails Phase IIb And Firm Says COVID-19 May Be To Blame

A Phase IIb trial testing IMC-1 for fibromyalgia failed to reach statistical significance on the primary pain endpoint, but one cohort showed an improvement and Virios intends to pursue the drug further.

Topics

Related Companies

Latest News
See All
UsernamePublicRestriction

Register

PS079328

Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel